Navigation Links
GeneCell International, Miami’s Preferred Cord Blood Laboratory, is Pleased to Announce That July is National Cord Blood Awareness Month
Date:8/1/2013

Miami, Florida (PRWEB) August 01, 2013

This year, GeneCell’s management team vowed to educate, encourage and raise awareness regarding the benefits of cord blood stem cell banking. Storing a newborn’s umbilical cord blood is a simple process and GeneCell is dedicated to be a partner in that process. GeneCell International’s pricing is reasonable, with considerable discounts and payment plans, it ensures that all expecting families will be able to afford it. There are no last-minute registration fees or medical courier fees.

According to the National Heart, Lung, and Blood Institute (NHLBI), National Cord Blood Awareness Month is a program that is promoted and its goal is to increase awareness in the banking of cord blood. The organization has supported research and safety with cord blood transplants. They encourage individuals to learn more about the treatments to advance the scientific knowledge in the field.

"Stem cells from bone marrow and umbilical cord blood have been used extensively in the clinical arena for more than 20 years to treat a variety of diseases, in fact today, approximately 80 different diseases can be treated with umbilical cord blood," said GeneCell's Director of Operations, Jose Cirino. "The clinical applications of umbilical cord blood have been growing by leaps and bounds considering 20 years ago it was thought that cord blood can be used to treat only a handful of different diseases. The other sources of these cells have recently been discovered and are being tested in a multitude of clinical trials including Type I Diabetes, Parkinson's disease, ALS, MS, heart attack, stroke as well as cosmetic applications."

GeneCell International specializes in the collection, transport, processing and cryogenic storage of adult stem cells from various sources including umbilical cord blood, dental pulp, and adipose tissue (fat) that can later be used to treat a variety of diseases. The laboratory is also involved in scientific research and development with a range of stem cells from various adult tissues. The facility is governed and inspected by the FDA as well several other regulating bodies to ensure the safety of these cellular therapies.

GeneCell International, LLC is a trusted provider in the collection, processing and storage of adult stem cells from various sources which have the potential to treat a variety of diseases and disorders. Headquartered in Miami, Florida and with local offices in Central Florida and international offices in Colombia, Costa Rica, Dominican Republic, Honduras, India, Peru, Puerto Rico, and Venezuela, GeneCell operates state-of-the-art laboratories and storage facilities for the cord blood and dental pulp of thousands of clients. For more information and to learn more about cord blood banking, cord tissue, dental pulp, adipose tissue or other GeneCell services, please visit our website at http://www.GeneCell.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb10986462.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GeneCell International’s Director of Operations, Jose Cirino, Organizes A Series of Educational Seminars with South Florida's Leading Obstetricians and Gynecologist
2. Lisa Lorraine Reyes Muñoz, GeneCell International’s Physician Relation's Manager Launches Educational Meetings for General Public on Umbilical Cord Blood Stem Cells
3. GeneCell International Gives Back to the Community by Participating in Local Elementary School’s Career Day
4. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
5. Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013
6. VWR International, LLC Acquires Sovereign Group
7. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
8. University of Colorado Cancer Center Study Shows the Preferred Feeding Method is not the Medically Best in Malnourished Pediatric Cancer Patients
9. Ekahau - A Preferred Provider of Real-Time Location Solutions - Is Awarded an Agreement with the Premier Healthcare Alliance
10. BioMed Realty Trust Declares Second Quarter 2012 Common Stock And Preferred Stock Dividends
11. Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Malden, MA (PRWEB) , ... February 24, 2017 ... ... disc replacement (TDR) procedures can be safely completed in an ambulatory surgery center ... and fusion (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)...  Driven by consumers, preference towards more natural ... growing categories, finds the recently published U.S. volume ... Multi-regional Market Analysis and Opportunities study by ... "Biotechnology actives are derived from natural ... for skin and hair care applications," explains ...
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
Breaking Biology Technology:
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
Breaking Biology News(10 mins):